ZAY Stock Overview
Engages in the research and development of graphene and related nanomaterials in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Zentek Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.59 |
| 52 Week High | CA$1.02 |
| 52 Week Low | CA$0.57 |
| Beta | 0.77 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -83.96% |
| 5 Year Change | 143.85% |
| Change since IPO | 63.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZAY | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.3% | 0.02% |
| 1Y | n/a | 8.2% | 19.6% |
Return vs Industry: Insufficient data to determine how ZAY performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how ZAY performed against the German Market.
Price Volatility
| ZAY volatility | |
|---|---|
| ZAY Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ZAY's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine ZAY's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 24 | Greg Fenton | www.zentek.com |
Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds. It is also developing graphene oxide synthesis and graphene synthesis.
Zentek Ltd. Fundamentals Summary
| ZAY fundamental statistics | |
|---|---|
| Market cap | €68.68m |
| Earnings (TTM) | -€7.40m |
| Revenue (TTM) | €23.54k |
2,918x
P/S Ratio-9.3x
P/E RatioIs ZAY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZAY income statement (TTM) | |
|---|---|
| Revenue | CA$35.31k |
| Cost of Revenue | CA$423.02k |
| Gross Profit | -CA$387.71k |
| Other Expenses | CA$10.71m |
| Earnings | -CA$11.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | -1,098.18% |
| Net Profit Margin | -31,443.53% |
| Debt/Equity Ratio | 3.5% |
How did ZAY perform over the long term?
See historical performance and comparison